<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469976</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000542546</org_study_id>
    <secondary_id>ECOG-E3506</secondary_id>
    <nct_id>NCT00469976</nct_id>
  </id_info>
  <brief_title>Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Trial of Enzastaurin Plus Carboplatin and Gemcitabine (ECoG) in Bevacizumab-Ineligible Patients and Enzastaurin Plus Carboplatin, Gemcitabine and Bevacizumab (B-ECoG) in Bevacizumab-Eligible Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,&#xD;
      such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,&#xD;
      such as bevacizumab, can block tumor growth in different ways. Some block the ability of&#xD;
      tumor cells to grow and spread. Others find tumor cells and help kill them or carry&#xD;
      tumor-killing substances to them. Giving enzastaurin together with carboplatin and&#xD;
      gemcitabine, with or without bevacizumab, may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving enzastaurin together with&#xD;
      carboplatin and gemcitabine, with or without bevacizumab, works in treating patients with&#xD;
      recurrent, stage IIIB, or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the progression-free survival in patients with recurrent or stage IIIB or IV&#xD;
           non-small cell lung cancer treated with carboplatin, gemcitabine, and enzastaurin with&#xD;
           or without bevacizumab.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the overall survival in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the response rate in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 treatment groups based&#xD;
      on eligibility for bevacizumab therapy.&#xD;
&#xD;
        -  Group 1 (bevacizumab-eligible): Patients receive carboplatin IV over 30 minutes and&#xD;
           bevacizumab IV over 30-90 minutes on day 1; gemcitabine hydrochloride IV over 30 minutes&#xD;
           on days 1 and 8; and oral enzastaurin hydrochloride 3 or 4 times daily on days 1-21 in&#xD;
           courses 1-6 and bevacizumab IV over 30-90 minutes on day 1 and oral enzastaurin&#xD;
           hydrochloride 3 times daily on days 1-21 in all subsequent courses.&#xD;
&#xD;
        -  Group 2 (bevacizumab-ineligible): Patients receive carboplatin, gemcitabine&#xD;
           hydrochloride, and enzastaurin hydrochloride as in group 1 in courses 1-6 and&#xD;
           enzastaurin hydrochloride alone 3 times daily on days 1-21 in all subsequent courses.&#xD;
&#xD;
      In both groups, courses repeat every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years and&#xD;
      then every 6 months for up to 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 99 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    ECOG will not proceed with activation&#xD;
  </why_stopped>
  <start_date>June 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 6 months (group 1)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival at 4.5 months (group 2)</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enzastaurin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Stage IIIB (with confirmed malignant pleural effusion), stage IV, or recurrent&#xD;
                  disease&#xD;
&#xD;
               -  Mixed tumors categorized by the predominant cell type are allowed provided no&#xD;
                  small cell elements exist&#xD;
&#xD;
                    -  Cytologic or histologic elements can be established on metastatic tumor&#xD;
                       aspirates or biopsy&#xD;
&#xD;
          -  Measurable disease as defined by RECIST criteria&#xD;
&#xD;
          -  No squamous cell carcinoma (group 1)&#xD;
&#xD;
          -  No history of brain metastases (group 1)&#xD;
&#xD;
               -  History of treated brain metastases allowed provided patient is not taking&#xD;
                  steroids and anti-seizure mediation (group 2)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN (≤ 5 times ULN with liver metastases)&#xD;
&#xD;
          -  AST and ALT ≤ 3 times ULN (≤ 5 times ULN with liver metastases)&#xD;
&#xD;
          -  INR &lt; 1.5 or PTT normal (group 1)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during (groups 1 and 2) and for 6&#xD;
             months after completion of study treatment (group 1)&#xD;
&#xD;
          -  No preexisting peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  Must be able to swallow tablets&#xD;
&#xD;
          -  No cardiovascular condition, including any of the following:&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Cerebrovascular ischemia or stroke within the past 6 months&#xD;
&#xD;
               -  NYHA congestive heart failure &gt; class II&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Serious cardiac arrhythmia requiring medication&#xD;
&#xD;
               -  Significant vascular disease&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease&#xD;
&#xD;
          -  No concurrent medical condition, psychiatric illness, or limitations that would limit&#xD;
             study compliance&#xD;
&#xD;
          -  No ongoing active infection or ongoing fever within the past 6 months&#xD;
&#xD;
          -  No history of uncontrolled hypertension, defined as blood pressure ≥ 150/90 mm Hg&#xD;
             despite being on a stable regimen of anti-hypertensive therapy&#xD;
&#xD;
          -  No serious nonhealing wound, ulcer, or bone fracture within the past 4 weeks&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No history of thrombotic or hemorrhagic disorders, bleeding diathesis, or coagulopathy&#xD;
             (group 1)&#xD;
&#xD;
          -  No bleeding &gt; grade 2 or any bleeding requiring intervention within the past 4 weeks&#xD;
             (group 1)&#xD;
&#xD;
          -  No history of gross hemoptysis (defined as &gt; ½ teaspoon of bright red blood) (group 1)&#xD;
&#xD;
          -  Urine protein:creatinine (UPC) ratio &lt; 1.0 by spot urinalysis&#xD;
&#xD;
               -  For UPC ratio &gt; 0.5, a 24-hour urine protein must be obtained and the urine&#xD;
                  protein level must be &lt; 1,000 mg (group 1)&#xD;
&#xD;
          -  None of the following conditions (group 1):&#xD;
&#xD;
               -  Grade II or greater peripheral vascular disease&#xD;
&#xD;
               -  Abdominal fistula&#xD;
&#xD;
               -  Gastrointestinal perforation&#xD;
&#xD;
               -  Intra-abdominal abscess&#xD;
&#xD;
          -  No known hypersensitivity to any component of bevacizumab (group 1)&#xD;
&#xD;
          -  No history of hypertensive crisis or hypertensive encephalopathy (group 1)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 4 weeks since prior major surgical procedure&#xD;
&#xD;
          -  More than 7 days since prior minor surgical procedure&#xD;
&#xD;
          -  No prior chemotherapy for advanced NSCLC&#xD;
&#xD;
               -  Postoperative adjuvant chemotherapy for previously resected NSCLC allowed if last&#xD;
                  dose was given &gt; 1 year ago&#xD;
&#xD;
          -  More than 3 weeks since prior radiation therapy and recovered&#xD;
&#xD;
          -  More than 3 weeks since prior immunotherapy and/or hormonal therapy (not including&#xD;
             hormone replacement therapy or contraceptives) and recovered&#xD;
&#xD;
          -  More than 14 days since prior enzyme inducing anti-epileptic drugs (EIAEDs)&#xD;
&#xD;
          -  More than 10 days since prior and no concurrent daily treatment with acetylsalicylic&#xD;
             acid (&gt; 325 mg/day) or NSAIDs known to inhibit platelet function for chronic&#xD;
             conditions (group 1)&#xD;
&#xD;
          -  No concurrent major surgical procedure (group 1)&#xD;
&#xD;
          -  No concurrent carbamazepine, phenobarbital, or phenytoin&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation (group 1)&#xD;
&#xD;
               -  Prophylactic anticoagulation of venous access devices is allowed&#xD;
&#xD;
          -  No concurrent treatment with dipyridamole, ticlopidine, clopidogrel, or cilostazol&#xD;
             (group 1)&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athanassios Argiris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chandra P. Belani, MD</last_name>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2007</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2015</last_update_posted>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

